CDK4 and chordoma: Besides, as there is a paucity of feasible biomarkers for the evaluation of CDK4/6 inhibitor sensitivity in chordoma (Passeri et al. 2022), another limitation of this research includes that the criteria for application of Palbociclib in the current case might be controversial.